Vical turns to vaccine pipeline after PhIII fail; CSL posts record net profits;

> Vical has shifted focus to its developmental vaccines after its melanoma immunotherapy failed Phase III. Piece

> Australian vaccine maker CSL posted a 19% rise in annual net profits to hit a record high of $1.2 billion. News

> Researchers have generated an Ad5 vector that is unaffected by neutralizing antibodies in mice. Abstract

> Cedars-Sinai Medical Center is running a Phase I trial to see if Copaxone can help Alzheimer's patients by stimulating immune cells. Release

> Researchers in Singapore have posted promising preclinical results for a dengue fever vaccine. Article

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.